Angiogenesis and vasculogenesis in rheumatoid arthritis

Current Opinion in Rheumatology

Volumn 22, Issue 3, 2010, Pages 299-306

  Szekanecz, Zoltán ^a   Besenyei, Timea ^a   Szentpétery, Ágnes ^a   Koch, Alisa E ^b,c  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b Veterans Administration   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Angiogenesis; Angiostasis; Rheumatoid arthritis; Therapy; Vasculogenesis

Indexed keywords

2 METHOXYESTRADIOL; 5,6,7,13 TETRAHYDRO 12 (3 HYDROXYPROPYL) 9 ISOPROPOXYMETHYLINDENO[2,1 A]PYRROLO[3,4 C]CARBAZOL 5(12H) ONE DIMETHYLGLYCINE ESTER; AXATINIB; AXITINIB; BENZOPHENONE; CEDIRANIB; CELASTROL; CHEMOKINE; CYTOKINE; FISETIN; FOCAL ADHESION KINASE; FUMAGILLIN; HYPOXIA INDUCIBLE FACTOR; IMATINIB; JUNCTIONAL ADHESION MOLECULE A; KRN 951; MACROPHAGE MIGRATION INHIBITION FACTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLERIXAFOR; PPI 2458; SERUM AMYLOID A; SORAFENIB; SPHINGOSINE KINASE; SUNITINIB; TOCILIZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VATALANIB;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; CHINESE MEDICINE; DRUG MECHANISM; HUMAN; HYPOXIA; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; VASCULAR DISEASE;

ANGIOGENESIS INHIBITORS; ANGIOGENIC PROTEINS; ARTHRITIS; ARTHRITIS, RHEUMATOID; BLOOD VESSELS; ENDOTHELIAL CELLS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR DISEASES;

EID: 77950285549     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e328337c95a     Document Type: Review

References (111)

1. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987; 235:442-447.
2. Colville-Nash PR, Scott DL. Angiogenesis and rheumatoid arthritis: pathogenic and therapeutic implications. Ann Rheum Dis 1992; 51:919-925.
3. Fearon U, Veale DJ. Angiogenesis in arthritis: methodological and analytical details. Methods Mol Med 2007; 135:343-357.
4. Kiselyov A, Balakin KV, Tkachenko SE. VEGF/VEGFR signalling as a target for inhibiting angiogenesis. Expert Opin Investig Drugs 2007; 16:83-107.
5. Koch AE. Review: angiogenesis: implications for rheumatoid arthritis. Arthritis Rheum 1998; 41:951-962.
6. Koch AE, Distler O. Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis. Arthritis Res Ther 2007; 9 (Suppl 2):S3.
7. Lainer-Carr D, Brahn E. Angiogenesis inhibition as a therapeutic approach for inflammatory synovitis. Nat Clin Pract Rheumatol 2007; 3:434-442.
8. Paleolog EM. The vasculature in rheumatoid arthritis: cause or consequence? Int J Exp Pathol 2009; 90:249-261.
9. Paleolog EM. Angiogenesis in rheumatoid arthritis. Arthritis Res 2002; 4 (Suppl 3):S81-S90.
10. Szekanecz Z, Koch AE. Mechanisms of disease: angiogenesis in inflammatory diseases. Nat Clin Pract Rheumatol 2007; 3:635-643.
11. Szekanecz Z, Koch AE. Macrophages and their products in rheumatoid arthritis. Curr Opin Rheumatol 2007; 19:289-295.
12. Szekanecz Z, Koch AE. Vascular involvement in rheumatic diseases: 'vascular rheumatology'. Arthritis Res Ther 2008; 10:224.
13. Szekanecz Z, Koch AE. Angiogenesis and its targeting in rheumatoid arthritis. Vascul Pharmacol 2009.
14. Szekanecz Z, Besenyei T, Paragh G, Koch AE. Angiogenesis in rheumatoid arthritis. Autoimmunity 2009; 42:563-573.
15. Avouac J, Uzan G, Kahan A, et al. Endothelial progenitor cells and rheumatic disorders. Joint Bone Spine 2008; 75:131-137.
16. Silverman MD, Haas CS, Rad AM, et al. The role of vascular cell adhesion molecule 1/very late activation antigen 4 in endothelial progenitor cell recruitment to rheumatoid arthritis synovium. Arthritis Rheum 2007; 56: 1817-1826.
17. Grisar J, Aletaha D, Steiner CW, et al. Endothelial progenitor cells in active rheumatoid arthritis: effects of tumour necrosis factor and glucocorticoid therapy. Ann Rheum Dis 2007; 66:1284-1288.
18. Paleolog E. It's all in the blood: circulating endothelial progenitor cells link synovial vascularity with cardiovascular mortality in rheumatoid arthritis? Arthritis Res Ther 2005; 7:270-272.
19. Veale DJ, Fearon U. Inhibition of angiogenic pathways in rheumatoid arthritis: potential for therapeutic targeting. Best Pract Res Clin Rheumatol 2006; 20:941-947.
20. Schoettler N, Brahn E. Angiogenesis inhibitors for the treatment of chronic autoimmune inflammatory arthritis. Curr Opin Investig Drugs 2009; 10:425-433.
21. Ablin JN, Boguslavski V, Aloush V, et al. Effect of anti-TNFalpha treatment on circulating endothelial progenitor cells (EPCs) in rheumatoid arthritis. LifeSci 2006; 79:2364-2369.
22. Kerekes G, Soltesz P, Der H, et al. Effects of biologics on vascular function and atherosclerosis associated with rheumatoid arthritis. Ann N Y Acad Sci 2009; 1173:814-821.
23. Reece RJ, Canete JD, Parsons WJ, et al. Distinct vascular patterns of early synovitis in psoriatic, reactive, and rheumatoid arthritis. Arthritis Rheum 1999; 42:1481-1484.
24. Kennedy A, Ng CT, Biniecka M, et al. Angiogenesis and blood vessel stability in inflammatory arthritis. Arthritis Rheum (in press).
25. Koch AE, Harlow LA, Haines GK, et al. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 1994; 152:4149-4156.
26. Shibuya M. Vascular endothelial growth factor-dependent and-independent regulation of angiogenesis. BMB Rep 2008; 41:278-286.
27. Kurosaka D, Hirai K, Nishioka M, et al. Correlation between synovial blood flow signals and serum vascular endothelial growth factor levels in patients with refractory rheumatoid arthritis. Mod Rheumatol 2009; 19:187-191.
28. Taylor PC, Sivakumar B. Hypoxia and angiogenesis in rheumatoid arthritis. Curr Opin Rheumatol 2005; 17:293-298.
29. Giatromanolaki A, Sivridis E, Maltezos E, et al. Upregulated hypoxia inducible factor-1alpha and-2alpha pathway in rheumatoid arthritis and osteoarthritis. Arthritis Res Ther 2003; 5:R193-R201.
30. Biniecka M, Kennedy A, Fearon U, et al. Oxidative damage in synovial tissue is associated with in vivo hypoxic status in the arthritic joint. Ann Rheum Dis 2009 [Epub ahead of print].
31. Ng CT, Biniecka M, Kennedy A, et al. Synovial tissue hypoxia and inflammation in vivo. Ann Rheum Dis Muz B, Khan MN, Kiriakidis S, Paleolog EM. Hypoxia. The role of hypoxia and HIF-dependent signalling events in rheumatoid arthritis. Arthritis Res Ther 2009; 11:201.
32. Westra J, MolemaG, Kallenberg CG. Hypoxia-inducible factor-1 as regulator of angiogenesis in rheumatoid arthritis: therapeutic implications. Curr Med Chem 2009.
33. Akhavani MA, Madden L, Buysschaert I, et al. Hypoxia upregulates angiogenesis and synovial cell migration in rheumatoid arthritis. Arthritis Res Ther 2009; 11:R64.
34. del Rey MJ, Izquierdo E, Caja S, et al. Human inflammatory synovial fibro-blasts induce enhanced myeloid cell recruitment and angiogenesis through a hypoxia-inducible transcription factor 1alpha/vascular endothelial growth factor-mediated pathway in immunodeficient mice. Arthritis Rheum 2009; 60:2926-2934.
35. Arany Z, Foo SY, Ma Y, et al. HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha. Nature 2008; 451:1008-1012.
36. Aljada A, O'Connor L, Fu YY, Mousa SA. PPAR gamma ligands, rosiglitazone and pioglitazone, inhibit bFGF-and VEGF-mediated angiogenesis. Angio genesis 2008; 11:361-367.
37. Piqueras L, Reynolds AR, Hodivala-Dilke KM, et al. Activation of PPARbeta/ delta induces endothelial cell proliferation and angiogenesis. Arterioscler Thromb Vasc Biol 2007; 27:63-69.
38. Yoo SA, Yoon HJ, Kim HS, et al. Role of placenta growth factor and its receptor flt-1 in rheumatoid inflammation: a link between angiogenesis and inflammation. Arthritis Rheum 2009; 60:345-354.
39. Colville-Nash PR, Willoughby DA. Growth factors in angiogenesis: current interest and therapeutic potential. Mol Med Today 1997; 3:14-23.
40. Rico MC, Rough JJ, Del Carpio-CanoFE, etal. Theaxisofthrombospondin-1, transforming growth factor beta and connective tissue growth factor: an emerging therapeutic target in rheumatoid arthritis. Curr Vasc Pharmacol.
41. Presta M, Andres G, Leali D, et al. Inflammatory cells and chemokines sustain FGF2-induced angiogenesis. Eur Cytokine Netw 2009; 20:39-50.
42. Strieter RM, Polverini PJ, Kunkel SL, et al. The functional role of the ELR motif in CXCchemokine-mediated angiogenesis. J Biol Chem 1995; 270:27348-27357.
43. SzekaneczZ, Pakozdi A, Szentpetery A, etal. Chemokines and angiogenesis in rheumatoid arthritis. Front Biosci (Elite Ed) 2009; 1:44-51.
44. Petit I, Jin D, Rafii S. The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis. Trends Immunol 2007; 28:299-307.
45. Pablos JL, Santiago B, Galindo M, et al. Synoviocyte-derived CXCL12 is displayed on endothelium and induces angiogenesis in rheumatoid arthritis. J Immunol 2003; 170:2147-2152.
46. Calatozzolo C, Maderna E, Pollo B, et al. Prognostic value of CXCL12 expression in 40 low-grade oligodendrogliomas and oligoastrocytomas. Cancer Biol Ther 2006; 5:827-832.
47. Agarwal SK, Brenner MB. Role of adhesion molecules in synovial inflammation. Curr Opin Rheumatol 2006; 18:268-276.
48. Jakobsson L, Claesson-Welsh L Vascular basement membrane components in angiogenesis-an act of balance. ScientificWorldJournal 2008; 8:1246-1249.
49. Rico MC, Castaneda JL, Manns JM, et al. Amelioration of inflammation, angiogenesis and CTGF expression in an arthritis model by a TSP1-derived peptide treatment. J Cell Physiol 2007; 211:504-512.
50. Koch AE, Szekanecz Z, Friedman J, et al. Effects of thrombospondin-1 on disease course and angiogenesis in rat adjuvant-induced arthritis. Clin Immunol Immunopathol 1998; 86:199-208.
51. Szekanecz Z, Haines GK, Harlow LA, et al. Increased synovial expression of transforming growth factor (TGF)-beta receptor endoglin and TGF-beta 1 in rheumatoid arthritis: possible interactions in the pathogenesis of the disease. Clin Immunol Immunopathol 1995; 76:187-194.
52. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994; 264:569-571.
53. Jacq L, Garnier S, Dieude P, et al. The ITGAV rs3738919-C allele is associated with rheumatoid arthritis in the European Caucasian population: a family-based study. Arthritis Res Ther 2007; 9:R63.
54. Ahnert P, Kirsten H. Association of ITGAV supports a role of angiogenesis in rheumatoid arthritis. Arthritis Res Ther 2007; 9:1 08.
55. Hollis-Moffatt JE, Rowley KA, Phipps-Green AJ, et al. The ITGAV rs3738919 variant and susceptibility to rheumatoid arthritis in four Caucasian sample sets. Arthritis Res Ther 2009; 11:R152.
56. Shahrara S, Castro-Rueda HP, Haines GK, Koch AE. Differential expression of the FAK family kinases in rheumatoid arthritis and osteoarthritis synovial tissues. Arthritis Res Ther 2007; 9:R112.
57. Kneilling M, Hultner L, Pichler BJ, etal. Targeted mast cell silencing protects against joint destruction and angiogenesis in experimental arthritis in mice. Arthritis Rheum 2007; 56:1806-1816.
58. NaikTU, Naik MU, Naik UP. Junctional adhesion molecules in angiogenesis. Front Biosci 2008; 13:258-262.
59. Rabquer BJ, Pakozdi A, Michel JE, et al. Junctional adhesion molecule C mediates leukocyte adhesion to rheumatoid arthritis synovium. Arthritis Rheum 2008; 58:3020-3029.
60. Brown PD. Matrix metalloproteinase inhibitors. Angiogenesis 1998; 1:142-154.
61. Brennan F, Beech J. Update on cytokines in rheumatoid arthritis. Curr Opin Rheumatol 2007; 19:296-301.
62. Morand EF, Leech M, Bernhagen J. MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis. Nat Rev Drug Discov 2006; 5:399-410.
63. Amin MA, Volpert OV, Woods JM, et al. Migration inhibitory factor mediates angiogenesis via mitogen-activated protein kinase and phosphatidylinositol kinase. Circ Res 2003; 93:321-329.
64. Pakozdi A, Amin MA, Haas CS, etal. Macrophage migration inhibitory factor: a mediator of matrix metalloproteinase-2 production in rheumatoid arthritis. Arthritis Res Ther 2006; 8:R132.
65. Lee MS, Yoo SA, Cho CS, et al. Serum amyloid A binding to formyl peptide receptor-like 1 induces synovial hyperplasia and angiogenesis. J Immunol 2006; 177:5585-5594.
66. Mullan RH, Bresnihan B, Golden-Mason L, etal. Acute-phase serum amyloid A stimulation of angiogenesis, leukocyte recruitment, and matrix degradation in rheumatoid arthritis through an NF-kappaB-dependent signal transduction pathway. Arthritis Rheum 2006; 54:105-114.
67. Migita K, Koga T, Torigoshi T, et al. Serum amyloid A protein stimulates CCL20 production in rheumatoid synoviocytes. Rheumatology (Oxford) 2009; 48:741-747.
68. Ruth JH, Shahrara S, Park CC, et al. Role of macrophage inflammatory protein-3alphaand its ligand CCR6 in rheumatoid arthritis. Lab Invest 2003; 83:579-588.
69. Yonesu K, Kawase Y, InoueT, etal. Involvement of sphingosine-1-phosphate and S1P1 in angiogenesis: analyses using a new S1P1 antagonist of nonsphingosine-1-phosphate analog. Biochem Pharmacol 2009; 77: 1011-1020.
70. Limaye V, Xia P, Hahn C, et al. Chronic increases in sphingosine kinase-1 activity induce a pro-inflammatory, pro-angiogenic phenotype in endothelial cells. Cell Mol Biol Lett 2009.
71. Choi ST, Kim JH, SeokJY, et al. Therapeutic effect of antivascular endothelial growth factor receptor I antibody in the established collagen-induced arthritis mouse model. Clin Rheumatol 2009; 28:333-337.
72. Grosios K, Wood J, Esser R, et al. Angiogenesis inhibition by the novel VEGF receptor tyrosine kinase inhibitor, PTK787/ZK222584, causes significant antiarthritic effects in models of rheumatoid arthritis. Inflamm Res 2004; 53:133-142.
73. Bongartz T, Coras B, Vogt T, et al. Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone: an open-label pilot study. Rheumatology (Oxford) 2005; 44:126-129.
74. Hirota SA, Beck PL, MacDonald JA. Targeting hypoxia-inducible factor-1 (HIF-1) signaling in therapeutics: implications for the treatment of inflammatory bowel disease. Recent Pat Inflamm Allergy Drug Discov 2009; 3:1-16.
75. Shankar J, Thippegowda PB, Kanum SA. Inhibition of HIF-1alpha activity by BP-1 ameliorates adjuvant induced arthritis in rats. Biochem Biophys Res Commun 2009; 387:223-228.
76. Kameda H, Ishigami H, Suzuki M, etal. Imatinib mesylate inhibits proliferation of rheumatoid synovial fibroblast-like cells and phosphorylation of Gab adapter proteins activated by platelet-derived growth factor. Clin Exp Immunol 2006; 144:335-341.
77. Koyama K, Hatsushika K, Ando T, et al. Imatinib mesylate both prevents and treats the arthritis induced by type II collagen antibody in mice. Mod Rheumatol 2007; 17:306-310.
78. Yin Y, Huang L, Zhao X, et al. AMD3100 mobilizes endothelial progenitor cells in mice, but inhibits its biological functions by blocking an autocrine/ paracrine regulatory loop of stromal cell derived factor-1 in vitro. J Cardiovasc Pharmacol 2007; 50:61-67.
79. Markham T, Mullan R, Golden-Mason L, et al. Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy. J Am Acad Dermatol 2006; 54:1003-1012.
80. Goedkoop AY, Kraan MC, Picavet DI, et al. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study. Arthritis Res Ther 2004; 6:R326-R334.
81. Nakahara H, Nishimoto N. Antiinterleukin-6 receptor antibody therapy in rheumatic diseases. Endocr Metab Immune Disord Drug Targets 2006; 6:373-381.
82. Ingber D, Fujita T, Kishimoto S, et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990; 348:555-557.
83. Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 2006; 54:258-265.
84. Hannig G, Bernier SG, Hoyt JG, et al. Suppression of inflammation and structural damage in experimental arthritis through molecular targeted therapy with PPI-2458. Arthritis Rheum 2007; 56:850-860.
85. Brahn E, Schoettler N, LeeS, Banquerigo ML. Involution of collagen-induced arthritis with an angiogenesis inhibitor, PPI-2458. J Pharmacol Exp Ther 2009; 329:615-624.
86. Ogrendik M. Effects of clarithromycin in patients with active rheumatoid arthritis. Curr Med Res Opin 2007; 23:515-522.
87. Yue L, Shen YX, Feng LJ, et al. Blockage of the formation of new blood vessels by recombinant human endostatin contributes to the regression of rat adjuvant arthritis. Eur J Pharmacol 2007; 567:166-170.
88. Huang XY, Chen FH, Li J, et al. Mechanism of fibroblast-like synoviocyte apoptosis induced by recombinant human endostatin in rats with adjuvant arthritis. Anat Rec (Hoboken) 2008; 291:1029-1037.
89. Mabjeesh NJ, Escuin D, LaVallee TM, et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003; 3:363-375.
90. Brahn E, Banquerigo ML, Lee JK, et al. An angiogenesis inhibitor, 2-methox-yestradiol, involutes rat collagen-induced arthritis and suppresses gene expression of synovial vascular endothelial growth factor and basic fibroblast growth factor. J Rheumatol 2008; 35:2119-2128.
91. Issekutz AC, Sapru K. Modulation of adjuvant arthritis in the rat by 2-methoxyestradiol: an effect independent of an antiangiogenic action. Int Immunopharmacol 2008; 8:708-716.
92. Plum SM, Park EJ, Strawn SJ, et al. Disease modifying and antiangiogenic activity of 2-methoxyestradiol in a murine model of rheumatoid arthritis. BMC Musculoskelet Disord 2009; 10:46.
93. Pan R, Dai Y, Gao X, Xia Y. Scopolin isolated from Erycibe obtusifolia Benth stems suppresses adjuvant-induced rat arthritis by inhibiting inflammation and angiogenesis. Int Immunopharmacol 2009 [Epub ahead of print]
94. Zhou YX, Huang YL. Antiangiogenic effect of celastrol on the growth of human glioma: an in vitro and in vivo study. Chin Med J (Engl) 2009; 122:1666-1673.
95. Lee JD, Huh JE, Jeon G, et al. Flavonol-rich RVHxR from Rhus verniciflua Stokes and its major compound fisetin inhibits inflammation-related cytokines and angiogenic factor in rheumatoid arthritic fibroblast-like synovial cells and in vivo models. Int Immunopharmacol 2009; 9:268-276.
96. Peichev M, Naiyer AJ, PereiraD, et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 2000; 95:952-958.
97. Freedman SB, Isner JM. Therapeutic angiogenesis for ischemic cardiovascular disease. J Mol Cell Cardiol 2001; 33:379-393.
98. Herbrig K, Haensel S, Oelschlaegel U, et al. Endothelial dysfunction in patients with rheumatoid arthritis is associated with a reduced number and impaired function of endothelial progenitor cells. Ann Rheum Dis 2006; 65:157-163.
99. Surdacki A, Martens-Lobenhoffer J, Wloch A, et al. Plasma asymmetric dimethylarginine is related to anticitrullinated protein antibodies in rheumatoid arthritis of short duration. Metabolism 2009; 58:316-318.
100. Yamaguchi J, Kusano KF, Masuo O, et al. Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation 2003; 107:1322-1328.
101. Wojakowski W, Tendera M, Michalowska A, et al. Mobilization of CD34/ CXCR4+, CD34/CD117+, c-met+ stem cells, and mononuclearcells expressing early cardiac, muscle, and endothelial markers into peripheral blood in patients with acute myocardial infarction. Circulation 2004; 110:3213-3220.
102. Fan Y, Ye J, Shen F, et al. Interleukin-6 stimulates circulating blood-derived endothelial progenitor cell angiogenesis in vitro. J Cereb Blood Flow Metab 2008; 28:90-98.
103. Grote K, Salguero G, Ballmaier M, et al. The angiogenic factor CCN1 promotes adhesion and migration of circulating CD34+ progenitor cells: potential role in angiogenesis and endothelial regeneration. Blood 2007; 110:877-885.
104. Oh IY, Yoon CH, Hur J, et al. Involvement of E-selectin in recruitment of endothelial progenitor cells and angiogenesis in ischemic muscle. Blood 2007; 110:3891-3899.
105. Sherer Y, Shoenfeld Y. Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol 2006; 2:99-106.
106. Szekanecz Z, Kerekes G, Der H, et al. Accelerated atherosclerosis in rheumatoid arthritis. Ann N Y Acad Sci 2007; 1108:349-358.
107. Akhavani MA, Larsen H, Paleolog E. Circulating endothelial progenitor cells as a link between synovial vascularity and cardiovascular mortality in rheumatoid arthritis. Scand J Rheumatol 2007; 36:83-90.
108. Pakozdi A, Besenyei T, Paragh G, et al. Endothelial progenitor cells in arthritis-associated vasculogenesis and atherosclerosis. Joint Bone Spine 2009 [Epub ahead of print]
109. Jacobsson LT,TuressonC, GulfeA, etal. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005; 32:1213-1 218.
110. Dixon WG, Watson KD, Lunt M, et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to antitumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007; 56:2905-2912.
111. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275:964-967.